|
Bipolar Disorder Therapeutics – Pipeline Assessment and Market Forecasts to 2018
MarketWatch (press release) In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar … and more » |
|
Bipolar Disorder Therapeutics – Pipeline Assessment and Market Forecasts to 2018
PR Newswire (press release) In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar … and more » |
|
UPDATE 1-Teva gets US okay to buy Cephalon with conditions
Reuters Cephalon's top-selling Provigil sleep disorder drug is set to lose patent protection next year, while adoption of a newer version, Nuvigil, has been disappointing. The FTC sued Cephalon in 2008, saying it broke the law by paying generic drug makers, … and more » |
|
FBI Solyndra Probe, Cephalon Subpoena, Barclays: Compliance
BusinessWeek Cephalon Inc. received a subpoena from the US Justice Department asking for information about the marketing of Nuvigil and Provigil, the company's best-selling medicines to promote wakefulness. Cephalon, based in Frazer, Pennsylvania, … |